NF1 and dermal neurofibroma: All reported mutations were validated by Sanger sequencing in the four samples (blood, breast cancer, MPNST, and dermal neurofibroma; Fig. 1, Table S2), except the insertion of cytosine in the NF1 gene (g.chr17:29,553,477) in the breast cancer, most probably due to repetitive sequences in that region leading to slippages in Sanger sequencing.